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Systemic lymph node metastasis is a rare event in malignant mesothelioma. It is even more exceptional when systemic lymph node
metastasis is the initial clinical presentation. Review of literature discloses only four cases in which metastatic lymphadenopathy
was the only symptom of malignant mesothelioma. We, herewith, report three cases where the initial diagnosis of malignant
mesothelioma was made by biopsy of enlarged lymph nodes, which were the only clinical presentation. Immunohistochemistry
played a pivotal role in elucidating the mesothelial origin of their unusual systemic lymph node metastasis.
1.Introduction
Malignant mesothelioma (MM) is an uncommon neoplasm
which is characterized by highly aggressive behavior and
poor prognosis [1]. The neoplasm predominantly involves
pleural and peritoneal cavities, with a smaller percentage
of cases arising in the pericardial sac and testicular tunica
vaginalis [2]. Clinically, the majority of patients have local
symptoms such as chest or abdominal pain and dyspnea,
depending on the site of origin. Occasionally, patients may
present with distant metastasis. Systemic lymphadenopathy,
however, is an exceeding rare initial presentation of this
disease [3]; thirteen cases have been reported in literature.
In four of those, systemic lymphadenopathy was the only
clinical manifestation [4–6].
In this report, we describe three additional cases of
primary peritoneal MM in which the initial diagnosis of the
disease was made by biopsy of neck, supraclavicular lymph
nodes, and axillary lymph nodes. Two cases were primary
from peritoneum and the third originated in the pleura.
2. Report of Cases
2.1. Case One. A 50-year-old male with no past medical
history presented with progressive enlargement of lymph
nodesinhisleftgroinandrightinferiorneckoveraperiodof
6months.PETscanshowedhighuptakeinseveralareassuch
as mediastinum, pericardial region, cardiophrenic angles,
supraclavicular area, internal mammary, perihepatic region,
and groin with standardized uptake values (SUVs) ranging
from 4.8 to 12.5. Most of these uptakes were interpreted
as presence of a malignant process probably malignant
lymphoma. Immediate assessment on ﬁne needle aspiration
cytology from left groin lymph node, however, ruled out
the diagnosis of malignant lymphoma. A subsequent core
biopsywasobtainedfromrightsupraclavicularnodeandwas
interpreted as metastatic malignant epithelial neoplasm to
lymph node. The neoplasm was characterized by a diﬀuse
growth of polygonal cells with well-deﬁned cell membranes
and dense eosinophilic cytoplasm. Nuclei were generally
single, and mitoses were scant (Figure 1). Tumor cells were
positive for cytokeratin (Figure 2), calretinin (Figure 3), D2-
40 (Figure 4), CD10, and CK5/6, focally positive for CK7
and CA-125, and negative for hepatocellular antigen, renal
carcinoma antigen, prostatic speciﬁc antigen, carcinoem-
bryonic antigen, HMB45, S100 protein, p63, CDX2, CK20,
thyroid transcription factor-1, inhibin, and alpha-feto pro-
tein by immunohistochemistry. Based on histomorpholgy
and immunophenotype, the diagnosis of metastatic malig-
nant mesothelioma was rendered. Retrospectively, review of2 Pathology Research International
Figure 1: Metastatic malignant mesothelioma to lymph node.
(H&E, 10×). The inset shows that the tumor cells are polygonal
withwell-deﬁnedcellmembranesanddenseeosinophiliccytoplasm
(H&E, 60×).
Figure 2: Metastatic malignant mesothelioma to lymph node. The
tumor cells are positive for cytokeratin by immunohistochemistry
(Keratin, 40×).
clinical and imaging studies conﬁrmed that the neoplasm
arised from peritoneum in perihepatic region.
2.2. Case Two. A 61-year-old male with no past medical
history presented with left neck lymphadenopathy. CT
scan showed multiple masses in the neck region, medi-
astinum and abdomen. Biopsy from neck mass revealed
several matted lymph nodes with complete replacement
by a nonlymphoid malignant neoplasm. The cells were
arranged in organoid and trabecular pattern with areas of
necrosis with perinodal tumoral involvement. The tumor
cells were large and polygonal with eosinophilic cytoplasm,
large prominent nucleoli, and numerous mitoses (Figure 5).
Tumor cells were positive for cytokeratin and calretinin
by immunohistochemistry. They were negative for CD20,
CD45, CD3, S-100 protein, thyroglobulin, carcinoembry-
onic antigen, human chorionic gonadotropin, keratin 8/18,
thyroid transcription factor-1, inhibin, and renal carcinoma
antigen. A diagnosis of metastatic malignant mesothelioma
Figure 3: Metastatic malignant mesothelioma to lymph node. The
tumor cells are positive for calretinin by immunohistochemistry
(Calretinin, 40×).
Figure 4: Metastatic malignant mesothelioma to lymph node. The
tumor cells are positive for D2-40 by immunohistochemistry (D2-
40, 40×).
was made. Retrospectively, review of prior CT scans revealed
that the neoplasm originated in pelvic peritoneum.
2.3. Case Three. Patient is a 69-year-old male who by
imaging proved to have mediastinal and left axillary lym-
phadenopathy. Biopsy of the axillary lymph node showed
a metastatic epithelial neoplasm morphologically consis-
tent with malignant mesothelioma. Positive immunohisto-
chemical reaction for calretinin and negative staining for
TTF-1 and CEA supported that diagnosis. Clinical and
imaging studies revealed left pleural thickening. A pleural
biopsy conﬁrmed the diagnosis of epithelioid malignant
mesothelioma.
3. Comment
Malignant mesothelioma is characterized by an aggressive
local behavior, such as pain and accumulation of ﬂuid in
the region of origin [7]. Rarely, this neoplasm metastasizesPathology Research International 3
Figure 5: Metastatic malignant mesothelioma to lymph node. The
tumor cells are large and polygonal with eosinophilic cytoplasm.
Theyhaveprominentnucleolianddisplaynumerousmitoses(H&E,
40×).
to lymph nodes, particularly early in the course of disease.
In the majority of cases, metastatic spread to the lymph
nodes is detected simultaneously with other conventional
clinical features of malignant mesothelioma, such as pain
and pleural or peritoneal eﬀusions. Malignant mesothelioma
presenting with peripheral lymphadenopathy as the initial
symptom is exceptionally rare. To our knowledge, there
have been 13 cases of MM with clinically apparent and
histopathologically proven lymph node metastasis [4–13]
but in only 4 of them, metastatic lymphadenopathy was
the initial clinical presentation. Two of these cases were
originatedinperitoneum[4],eachfrompleura[6],andperi-
cardium [5]. In our case one, PET scan showed numerous
systemic enlarged lymph nodes, with the largest lymph node
present at the mediastinum. Retrospectively, the area with
high standardized uptake values present at the perihepatic
regionwasconsideredtobetheprimarysiteoftheneoplasm.
Similarly, in our case two, retrospective analysis of imaging
studies revealed the site of origin. In our case three, the
biopsy from pleural surface conﬁrmed the diagnosis of MM
whichwasinitiallymadebysamplingpatient’saxillarylymph
node.
When one confronts a metastatic epithelial neoplasm
to a lymph node with evidence of a primary site, a
malignant mesothelioma is usually not on the list of
potential diﬀerential diagnoses. A combination of histomor-
phology along with an appropriate immunohistochemical
tests, however, may elucidate the mesothelial origin of
such rare metastasis. Immunohistochemistry is the most
helpful ancillary test in conﬁrmation of the diagnosis,
particularly in separating MM from adenocarcinoma. Most
usefulmarkersinourexperiencefromMMarecalretininand
D2-40 and negative reaction for CEA, MOC-31, and TTF-1
[14, 15].
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